Researchers have developed a new treatment called OcuRing™-K, which may change how people manage pain after cataract surgery. This innovative, drop-less therapy uses a bio-erodible ring that delivers medication directly to the eye during surgery. By providing sustained release of the anti-inflammatory drug ketorolac, OcuRing™-K aims to reduce the need for traditional eye drops that many patients struggle to use consistently after their procedure.

This development is significant for anyone undergoing cataract surgery, which is one of the most common surgeries worldwide. The current recovery process often involves weeks of using multiple eye drops, which can be inconvenient and lead to inconsistent treatment. OcuRing™-K could simplify post-operative care, potentially improving pain management and reducing inflammation, leading to a smoother recovery experience for patients.

The research is still in its early stages, as the U.S. Food and Drug Administration has just cleared the way for a Phase II clinical trial. This trial will assess the effectiveness and safety of OcuRing™-K in a larger group of patients. While the initial findings are promising, it’s important to note that the treatment has not yet been proven in widespread human use.

If you are preparing for cataract surgery, you might want to keep an eye on developments related to OcuRing™-K. While it’s not yet available, this new approach could eventually offer a more manageable way to handle post-surgical pain and inflammation.

Source: globenewswire.com